Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells

Colorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neopla...

Full description

Bibliographic Details
Main Authors: Sandra Gessani, Filippo Belardelli
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/10/1491
id doaj-de889b8ed23f432fa256f95eb5e67455
record_format Article
spelling doaj-de889b8ed23f432fa256f95eb5e674552020-11-25T02:16:00ZengMDPI AGCancers2072-66942019-10-011110149110.3390/cancers11101491cancers11101491Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic CellsSandra Gessani0Filippo Belardelli1Center for Gender-Specific Medicine, Istituto Superiore di Sanità, 00161 Rome, ItalyInstitute of Translational Pharmacology, CNR, 00131 Rome, ItalyColorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neoplastic cells, including immune cells. Several immune dysfunctions were described in CRC patients at different disease stages. Many studies underline the role of microbiota, obesity-related inflammation, diet and host reactive cells, including dendritic cells (DC), in CRC pathogenesis. Here, we focused on DC, the main cells linking innate and adaptive anti-cancer immunity. Variations in the number and phenotype of circulating and tumor-infiltrating DC have been found in CRC patients and correlated with disease stages and progression. A critical review of DC-based clinical studies and of recent advances in cancer immunotherapy leads to consider new strategies for combining DC vaccination strategies with check-point inhibitors, thus opening perspectives for a more effective management of this neoplastic disease.https://www.mdpi.com/2072-6694/11/10/1491colorectal cancerdendritic cellsimmunotherapypathogenesisrisk factors
collection DOAJ
language English
format Article
sources DOAJ
author Sandra Gessani
Filippo Belardelli
spellingShingle Sandra Gessani
Filippo Belardelli
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
Cancers
colorectal cancer
dendritic cells
immunotherapy
pathogenesis
risk factors
author_facet Sandra Gessani
Filippo Belardelli
author_sort Sandra Gessani
title Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
title_short Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
title_full Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
title_fullStr Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
title_full_unstemmed Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
title_sort immune dysfunctions and immunotherapy in colorectal cancer: the role of dendritic cells
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-10-01
description Colorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neoplastic cells, including immune cells. Several immune dysfunctions were described in CRC patients at different disease stages. Many studies underline the role of microbiota, obesity-related inflammation, diet and host reactive cells, including dendritic cells (DC), in CRC pathogenesis. Here, we focused on DC, the main cells linking innate and adaptive anti-cancer immunity. Variations in the number and phenotype of circulating and tumor-infiltrating DC have been found in CRC patients and correlated with disease stages and progression. A critical review of DC-based clinical studies and of recent advances in cancer immunotherapy leads to consider new strategies for combining DC vaccination strategies with check-point inhibitors, thus opening perspectives for a more effective management of this neoplastic disease.
topic colorectal cancer
dendritic cells
immunotherapy
pathogenesis
risk factors
url https://www.mdpi.com/2072-6694/11/10/1491
work_keys_str_mv AT sandragessani immunedysfunctionsandimmunotherapyincolorectalcancertheroleofdendriticcells
AT filippobelardelli immunedysfunctionsandimmunotherapyincolorectalcancertheroleofdendriticcells
_version_ 1724893434699841536